Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 17, 2016
FDA Continues Site Tours Program
Author(s)Pharmaceutical Technology Editors
The agency is continuing CDER’s Regulatory Project Management Site Tours and Regulatory Interaction Program.
Advertisement
On Feb. 9, 2016, FDA’s Center for Drug Evaluation and Research (CDER) announced the continuation of the Regulatory Project Management Site Tours and Regulatory Interaction Program, also known as the Site Tours Program. The program is part of CDER’s training and development programs designed to promote high performance and enhance review efficiency by providing firsthand exposure to the industry’s drug development processes.
The Site Tours Program allows small groups of regulatory project managers to observe the manufacturing operations of participating pharmaceutical companies in order to gain more understanding of manufacturing processes. The regulatory project managers also participate in workshops with industry counterparts to learn about a team approach to drug development.
Pharmaceutical companies interested in participating in the program should submit proposed agendas to FDA by April 11, 2016.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement